Get Started in Minutes
How Epclusa Copay Assistance Works
1 – Check Your Coverage/Benefits Verification
Our team of expert billers finds the best avenues of coverage that minimize out-of-pocket costs.
2 – Transfer Prescription to AmeriPharma
We process your prescription by working with your previous pharmacy or prescriber, making the transition quick and easy.
3 – Prior Authorization
Our team of specialists obtains approval from your insurance companies within 24 to 72 hours.
4 – Copay Assistance & Financial Aid
We secure financial aid and decrease copays, out-of-pocket expenses, and high deductibles. To date, AmeriPharma Specialty Care has secured $55 million in financial assistance for our patients.
5 – Nursing Care Coordination
AmeriPharma puts your schedule and home environment first when scheduling and coordinating one of our specialized nurses for your in-home infusions.
6 – Delivery Coordination
Medications are always delivered in strict compliance with the specific requirements for immune globulin shipping. Next-day and overnight cold-chain deliveries are coordinated around your schedule.
What Is Epclusa?
Epclusa (sofosbuvir and velpatasvir) is a prescription medication that is used in the treatment of chronic hepatitis C. Epclusa is used to treat patients with compensated cirrhosis or without cirrhosis. It can also be used in combination with ribavirin in patients with decompensated cirrhosis.
Epclusa contains two antiviral medications, sofosbuvir and velpatasvir. Prior to administration, it is recommended to get tested for hepatitis B (HBV) as this medication can cause reactivation of hepatitis B. This medication can be given to adults and pediatric patients that are 3 years and older that suffer from hepatitis C. This medication interacts with other medications, and it is important to check for drug-drug interactions before administration of this medication.
How Is Epclusa Used?
Epclusa is the first oral medication that is used for the treatment of hepatitis C genotypes 1 through 6. This medication is a combination antiviral medication that contains sofosbuvir and velpatasvir.
In patients that are experiencing compensating cirrhosis and patients that are not experiencing cirrhosis, the duration of treatment is 12 weeks. For patients with decompensated cirrhosis, the patient will be on Epclusa and ribavirin for 12 weeks.
This medication can also be given to pediatric patients. Dosing for pediatric patients (3 years and older) is dependent on the patient’s weight. Tablets and oral pellets are available for pediatric patients.
Copay and Financial Assistance
AmeriPharma Specialty Care alleviates financial burdens for patients and their families
Advanced software locates funding sources to match you with top-dollar foundation programs
One of our copay assistance specialists will assist with the application process
Automatic updates will be sent to you and your physician on the status of the funding
Epclusa Side Effects
- Signs of liver problems such as upset stomach, dark urine, light-colored stools, or yellow skin or eyes
Directions for Use
Epclusa is a tablet that is taken orally once a day with or without food. It is a combination tablet that contains 400 mg of sofosbuvir and 100 mg of velpatasvir. Eplcusa should not be coadministered with amiodarone as serious symptomatic bradycardia (slowing of heart rate) can occur. The solubility of velpatasvir may decrease as pH increases. Patients should also not concomitantly take proton pump inhibitors, antacids, or H2-receptor antagonists while on Epclusa. This medication may also interact with other medications that will cause the medication to decrease its therapeutic effect. It is necessary to check for drug-drug interactions prior to administration of this medication. Medications such as St. John’s Wort, carbamazepine, digoxin, and topotecan can also affect the efficacy of Epclusa. This medication can also be given to pediatric patients depending on the patient’s weight.
Dosing information for pediatric patients:
- <17 kg: Oral pellets: Oral: Sofosbuvir 150 mg/velpatasvir 37.5 mg once daily.
- 17 to <30 kg: Oral pellets, tablet: Oral: Sofosbuvir 200 mg/velpatasvir 50 mg once daily.
- ≥30 kg: Oral pellets, tablet: Oral: Sofosbuvir 400 mg/velpatasvir 100 mg once daily.
For pediatric patients younger than 6 years old, this medication can be given with food to help with taste. The oral pellets can be sprinkled on non-acidic foods such as pudding, mashed potatoes, or ice cream and given within 15 minutes after mixing. The medication should not be chewed or crushed but swallowed whole.